Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer

Rhea-AI Summary

Guardant Health announced that its ECLIPSE Study data will be presented as a late-breaking abstract at Digestive Disease Week (DDW) from May 6-9, 2023, in Chicago. The study focuses on the performance of the Shield blood test for early-stage colorectal cancer detection in asymptomatic patients. Co-CEO AmirAli Talasaz emphasized the test's potential to increase screening rates, which remain low despite existing modalities. Gastroenterologist Daniel Chung also highlighted the need for less invasive screening methods. The acceptance of the ECLIPSE Study signifies a robust research effort, and further data will be shared during the conference. Guardant Health aims to improve adherence to cancer screening through its innovative technologies.

Positive

• Acceptance of the ECLIPSE Study as a late-breaking abstract at DDW indicates significant research validation.
• The Shield blood test targets early-stage colorectal cancer detection, potentially increasing screening rates.

Negative

• None.

The data from the pivotal ECLIPSE Study accepted as a late-breaking abstract highlights the performance of the Shield™ blood test in detecting colorectal cancer in asymptomatic patients

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC), including the acceptance of the ECLIPSE study as a late-breaking abstract, at Digestive Disease Week (DDW) taking place in Chicago, Illinois on May 6-9, 2023.

“Despite multiple screening modalities for colorectal cancer, screening rates remain stubbornly low leaving many cancers undetected. A blood test that can accurately detect CRC represents a significant opportunity to overcome some of the known challenges with patient adherence,” said AmirAli Talasaz, Guardant Health co-CEO. “We are thrilled that DDW has accepted the ECLIPSE study, one of the largest studies of its kind, as a late-breaking abstract, and we look forward to sharing this new data with the healthcare community at this year’s meeting.”

“The need for a convenient, less invasive way to screen for CRC is great, and an accurate blood test can play a critical role in improving screening rates, especially for those reluctant to get screened,” said Daniel Chung, MD, gastroenterologist at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. “I look forward to presenting at DDW and sharing new data from the ECLIPSE Study on the performance and potential of the Shield blood test to help improve adherence to screening."

The ECLIPSE Study late-breaking abstract and one additional abstract highlighting the potential of Guardant Health’s blood-based screening technology are now available online through the DDW meeting planner. The presentation on Tuesday, May 9 will include further data and trial design analysis beyond what is included in the online abstract. Details of the presentations are as follows:

Abstract	Session	Title
Tuesday, May 9 | 9:00-9:15am CT
#3910067	DDW Clinical Late Breaking Session #5095	Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer in an Average Risk Population Presenter: Daniel Chung, MD, gastroenterologist at Massachusetts General Hospital and professor of medicine at Harvard Medical School
Tuesday, May 9 | 12:30-1:30pm CT
#Tu1132	Poster Session #9050	Assessment of an Early Version Blood Based Multimodal cfDNA Assay for the Detection of Colorectal Cancer Incorporating the Assessment of ctDNA Genomic Alterations and Epigenomic Modifications

About Digestive Disease Week®

Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 6-9, 2023. The meeting showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.

Guardant Health Forward-Looking Statement

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2022, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230421005227/en/

Guardant Health Contacts

Investor Contact:

Alex Kleban

investors@guardanthealth.com

+1 657-254-5417

Media Contact:

Breen Weir

press@guardanthealth.com

+1 843-384-0095

Source: Guardant Health, Inc.

FAQ

What is the ECLIPSE Study and its significance for Guardant Health (GH)?

The ECLIPSE Study is an investigation into the performance of Guardant Health's Shield blood test for detecting early-stage colorectal cancer, accepted as a late-breaking abstract for presentation at DDW 2023.

When will Guardant Health present its findings at the DDW conference?

Guardant Health will present findings from the ECLIPSE Study on May 9, 2023, during the late-breaking session.

What impact does the Shield blood test have on colorectal cancer screening rates?

The Shield blood test aims to improve screening rates for colorectal cancer by offering a convenient and less invasive testing option.

What are the potential benefits of Guardant Health's blood test technology?

Guardant Health's blood test technology could enhance early cancer detection, thereby improving patient outcomes and reducing healthcare costs.